PR Newswire
OAKVILLE, ON, Feb. 1, 2017
OAKVILLE, ON, Feb. 1, 2017 /PRNewswire/ - Concordia International Corp. ("Concordia" or the "Company") (NASDAQ: CXRX) (TSX: CXR), an international specialty pharmaceutical company focused on generic and legacy pharmaceutical products and orphan drugs, today announced that it has paid the second and final installment of its earn-out to Cinven1 relating to Concordia's October 2015 acquisition of Amdipharm Mercury Limited.
Today's payment of £72 million, plus interest of approximately £1.5 million, was paid with cash on hand.